Antipathy from figures close to Trump toward mRNA technology, which underlies Moderna’s products and pipeline, has weighed on the company’s valuation.
Continue Reading
View Comments
Moderna Stock Jumps as NIH Chief Tempers Administration’s Attack on mRNA
Published 2 months ago
Aug 13, 2025 at 7:16 PM
Neutral
Auto